TY  -  JOUR
AU  -  Bruno, Giuseppe
AU  -  Perelli, Serena
AU  -  Palazzo, Giulia
AU  -  De Vita, Giuseppina
AU  -  Buccoliero, Giovanni Battista
T1  -  Oral antivirals against Sars-CoV-2 
in multiple myeloma outpatients: a case series
PY  -  2023
Y1  -  2023-01-01
DO  -  10.1701/3939.39230
JO  -  Recenti Progressi in Medicina
JA  -  Recenti Prog Med
VL  -  114
IS  -  1
SP  -  815
EP  -  817
PB  -  Il Pensiero Scientifico Editore
SN  -  2038-1840
Y2  -  2026/04/23
UR  -  http://dx.doi.org/10.1701/3939.39230
N2  -  Summary. Recently, the therapeutic armamentarium against Sars-CoV-2 has been enriched with oral antivirals that can be used in the early phases of covid-19. Real-life data on their efficacy in multiple myeloma (Mm) outpatients with mild-to-moderate covid-19 are lacking. We described the clinical outcomes at 30 days in Mm subjects with covid-19 treated with oral antivirals. Nirmatrelvir/r was prescribed in 10 subjects whereas molnupiravir in 5. Despite two hospitalizations were reported, we did not observe deaths due to covid-19 in this vulnerable group. Our preliminary observations reinforce the early use of oral antivirals as a useful means to contain severe covid-19 in high-risk patients such as Mm individuals characterized by an impaired immune response.
ER  -